8-K
filed June 16, 2023, 7:59 PM ET
ticker BNGO
CIK 0001411690
other material
confidence high
sentiment neutral
materiality 0.70
Bionano shareholders approve reverse split authorization; directors elected
Bionano Genomics, Inc.
- Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-10 at board's discretion.
- Proposal 4: 2.064B votes for, 1.077B against, 0.936M abstain (including Series A Preferred votes).
- Elected Class II directors: Albert Luderer, Kristiina Vuori, Hannah Mamuszka for three-year terms.
- Advisory vote on executive compensation passed with 28.96M for, 25.69M against.
- Ratified BDO USA as independent auditor for FY2023 with 123.52M for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bionano Genomics, Inc. shareholders approved Approval of a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-10 at the 2023-06-14 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
The Company’s stockholders approved a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect, at the option of the Company’s Board of Directors, a reverse stock split of the Company’s common stock at a ratio between 1-for-5 and 1-for-10, inclusive, as determined by the Company’s Board of Directors in its sole discretion.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bionano Genomics, Inc. shareholders approved Election of Class II Directors at the 2023-06-14 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bionano Genomics, Inc. shareholders approved Advisory approval of the compensation of the Company’s named executive officers at the 2023-06-14 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bionano Genomics, Inc. shareholders approved Authorization to adjourn the Annual Meeting to solicit additional proxies if necessary at the 2023-06-14 meeting.
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
The Company’s stockholders approved the authorization to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 4.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Bionano Genomics, Inc. shareholders approved Ratification of the selection of BDO USA, LLP as independent registered public accounting firm at the 2023-06-14 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-14
Exact text from the filing
The Company’s stockholders ratified the selection of BDO USA, LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.